Quantcast

Heptares to Present at UBS Global Healthcare Conference and Upcoming Scientific Events

May 15, 2014

LONDON and BOSTON, May 15, 2014 /PRNewswire/ –

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and
development company, notes that Fiona Marshall, Heptares’ Chief Scientific Officer and
co-founder, will give a company presentation at the UBS Global Healthcare Conference
[https://www.ubs.com/global/en/investment-bank/key-investor-conferences/americas.html ] in
New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 19 May.

In addition, senior scientists from Heptares will give scientific presentations at the
following industry meetings over the coming weeks:

The 34th National Medicinal Chemistry Symposium [http://wizard.musc.edu/nmcs2014.html
] (Charleston, SC, USA, 18-21 May)

Dr John Christopher, Heptares’ Associate Director Chemistry, will present “Case
Studies in GPCR Drug Design” at 1:30pm EDT on Wednesday 21 May.

14th Annual Structure-Based Drug Design
[http://www.healthtech.com/sbd/overview.aspx?c=520 ] (Boston, MA, USA, 21-22 May)

Dr Jon Mason, Heptares’ Head of Computational Chemistry will present “High End GPCR
Design: Crafted Ligand Design and Druggability Analysis Using Protein Structure,
Lipophilic Hotspots and Explicit Water Networks” at 2:05pm EDT on Wednesday 21 May.

GTC GPCR Structure, Function and Drug Discovery
[https://www.gtcbio.com/conference/gpcr-overview ] (Boston, MA, USA, 22-23 May)

Dr Jon Mason will present “Structure Based Drug Discovery Applied to GPCRs” at 1:15pm
EDT on

Thursday 22 May.

For a full list of events at which Heptares will be present, please visit

http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically
challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked
to a wide range of human diseases. Leveraging our proprietary structure-based drug design
technology platform, we have built an exciting pipeline of novel drug candidates with the
potential to transform the treatment of serious diseases, including Alzheimer’s disease,
ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist,
MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM
Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda
Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.

SOURCE Heptares Therapeutics


Source: PR Newswire



comments powered by Disqus